GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Return-on-Tangible-Asset

Eris Lifesciences (BOM:540596) Return-on-Tangible-Asset : 8.80% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Eris Lifesciences's annualized Net Income for the quarter that ended in Mar. 2024 was ₹2,838 Mil. Eris Lifesciences's average total tangible assets for the quarter that ended in Mar. 2024 was ₹32,253 Mil. Therefore, Eris Lifesciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 8.80%.

The historical rank and industry rank for Eris Lifesciences's Return-on-Tangible-Asset or its related term are showing as below:

BOM:540596' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 16.75   Med: 35.64   Max: 53.03
Current: 18.37

During the past 12 years, Eris Lifesciences's highest Return-on-Tangible-Asset was 53.03%. The lowest was 16.75%. And the median was 35.64%.

BOM:540596's Return-on-Tangible-Asset is ranked better than
94.46% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.76 vs BOM:540596: 18.37

Eris Lifesciences Return-on-Tangible-Asset Historical Data

The historical data trend for Eris Lifesciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Return-on-Tangible-Asset Chart

Eris Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.90 39.08 31.53 25.70 16.75

Eris Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.99 26.08 28.71 23.90 8.80

Competitive Comparison of Eris Lifesciences's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Return-on-Tangible-Asset falls into.



Eris Lifesciences Return-on-Tangible-Asset Calculation

Eris Lifesciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=3919.83/( (14548.83+32252.99)/ 2 )
=3919.83/23400.91
=16.75 %

Eris Lifesciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=2838.48/( (0+32252.99)/ 1 )
=2838.48/32252.99
=8.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Eris Lifesciences  (BOM:540596) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Eris Lifesciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Eris Lifesciences (BOM:540596) Business Description

Traded in Other Exchanges
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines